RenovoRx's TIGeR-PaC Trial Enrolls Patients at Northwell Health Cancer Institute
核心洞察
RenovoRx's Phase III TIGeR-PaC trial, evaluating RenovoCath (搜索)'s delivery of gemcitabine for locally advanced pancreatic cancer (搜索) (LAPC), is now enrolling patients at Northwell Health Cancer Institute (搜索).
The TIGeR-PaC trial is a pivotal study designed to assess the safety and efficacy of targeted intra-arterial chemotherapy using RenovoCath (搜索) in LAPC patients.
Northwell Health Cancer Institute (搜索) joins a network of clinical sites across the United States participating in the TIGeR-PaC trial, expanding patient access to this innovative treatment approach.
RenovoRx, a biopharmaceutical company focused on novel targeted cancer therapies, announced that the Northwell Health Cancer Institute (搜索) (NHCI) in New Hyde Park, NY, is now enrolling patients in its Phase III TIGeR-PaC clinical trial. This pivotal trial is evaluating the company's RenovoCath (搜索) delivery system in conjunction with gemcitabine for the treatment of locally advanced pancreatic cancer (搜索) (LAPC).
The TIGeR-PaC trial is a randomized, controlled, multi-center study designed to assess the safety and efficacy of RenovoCath (搜索)'s intra-arterial delivery of gemcitabine, compared to systemic chemotherapy, in patients with LAPC. The primary endpoint of the trial is overall survival. Secondary endpoints include progression-free survival, objective response rate, and quality of life.
Pancreatic cancer (搜索) remains a significant challenge in oncology, with LAPC representing a particularly difficult-to-treat stage of the disease. Current treatment options for LAPC often involve systemic chemotherapy, which can be associated with significant side effects and limited efficacy. The TIGeR-PaC trial aims to address this unmet need by delivering chemotherapy directly to the tumor site, potentially improving treatment outcomes while minimizing systemic toxicity.
NHCI joins a growing network of clinical sites across the United States participating in the TIGeR-PaC trial. This expansion aims to accelerate patient enrollment and facilitate the timely completion of this important study. The results of the TIGeR-PaC trial could potentially lead to a new standard of care for patients with LAPC.